Skip to content
Case report Open access

A Rare Case of Fulminant Myocarditis Caused by Epstein-Barr Virus Infection in a Middle-Aged Man.

Sep 2026 · Clinical Laboratory · Vol 72 9, pp. 2003-2006 · 0 citations
Medicine

TL;DR

The risk of FM precipitated by EBV infection should not be underestimated and Prompt recognition, targeted therapy, and early circulatory support may avert fatal outcomes.

Abstract

Background

Fulminant myocarditis (FM) is a highly lethal syndrome of abrupt, diffuse cardiac inflammation that precipitates rapid-onset hemodynamic collapse. FM caused by Epstein-Barr virus (EBV) is rare and infrequently reported.

Methods

We reported a case of EBV-related FM in a man with respiratory and circulatory failure.

Results

The clinical diagnosis was made based on the patient's signs, ECG, ECHO, and significantly elevated levels of inflammatory factors and myocardial injury markers. The etiology was confirmed by mNGS detection of EBV DNA. The patient was successfully treated with VA-ECMO combination with medication therapy.

Conclusions

The risk of FM precipitated by EBV infection should not be underestimated. Prompt recognition, targeted therapy, and early circulatory support may avert fatal outcomes.

Read PDF

Similar papers

Open access Sep 2026

A rare case of fatal lymphocytic myocarditis in a young female: an autopsy report

Lymphocytic myocarditis (LM) is an inflammatory disease of the heart muscle most frequently associated with viral infections and autoimmune disorders. It is a rare but potentially lethal cause of sudden cardiac arrest, particularly in young individuals. We present an uncommon case of fulminant LM in a 13‑year‑old femal...

R. Richard, N. Alagarasan, Mathew Deepu et al. · 0 citations
Open access Sep 2026

MULTIFOCAL TUBERCULOSIS COMPLICATED WITH MACROPHAGE ACTIVATION SYNDROME (MAS): A CASE REPORT

Macrophagic activation syndrome is a rare, severe and often fatal immunological complication associated with a wide range of conditions such as: infections, cancers and auto immune diseases. We report a case of a young patient of 22 years old, admitted for acute pancreatitis in a febrile context and poor general condit...

Haussam el Haouari, D. Zagaouch, Zakaria Guennoun et al. · 0 citations
Case report Open access Sep 2026

Legionella Myocarditis with Reversible Left Ventricular Dysfunction in a Patient Receiving Adalimumab: A Case Report.

Legionella pneumophila is a well-recognized cause of community-acquired pneumonia, but its capacity to cause extrapulmonary complications, including myocarditis, remains underappreciated. Myocarditis is among the rarest and most serious cardiac manifestations of Legionella infection and may be underdiagnosed in critica...

A. Alzubi, M. Shelig, Y. Hegazy et al. · 0 citations
Open access Sep 2026

Fulminant Immune-Mediated Necrotising Myopathy with Multi-Organ Failure in a Previously Healthy Adult: A Case Report

Immune-mediated necrotizing myopathy (IMNM) is a severe inflammatory myopathy characterized by rapidly progressive weakness, markedly elevated creatine phosphokinase (CPK) levels, and myofiber necrosis with minimal inflammatory infiltrates. Early diagnosis is essential due to the risk of respiratory compromise, systemi...

Ramanan Sampavi, N. Herath, Tharindu Sisilarathna et al. · 0 citations
Case report Aug 2026

Fatal Rickettsial Multiorgan Dysfunction in an Adolescent Despite Standard Antimicrobial Therapy: A Case Report.

In rickettsial-endemic settings, clinicians should retain a high index of suspicion for these infections in patients presenting with undifferentiated febrile illness and retain a high index of suspicion for these infections in patients presenting with undifferentiated febrile illness.

Jitendra Singh, Keshav Suman, A. Dinkar et al. · 0 citations
Review Open access Aug 2026

Giant cell myocarditis: from immune pathogenesis to contemporary management

Giant cell myocarditis (GCM) is a rare but devastating inflammatory cardiac disease characterized by rapid hemodynamic deterioration, malignant arrhythmias, and high rates of death or heart transplantation. Without immunosuppressive treatment, median transplant-free survival is approximately three months. Current evide...

I. Vosko, M. Wallner · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.